ReviewCancers2021
Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis.Frontiers in oncology · 2023Pooled it
- Unlocking the potential of microRNA as predictive biomarkers for efficacy and adverse events in immune checkpoint inhibitor therapy (Review).Molecular medicine reports · 2026Review
- Article
- Evolving non-invasive biomarkers in NSCLC immunotherapy: integrating liquid biopsy and multi-omics profiling for precision oncology.Frontiers in immunology · 2026Review
- Circulating tumor DNA in lung cancer: a bibliometric analysis of studies published from 2001 to 2024.Journal of thoracic disease · 2025Article
- Review
- Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders.Frontiers in pharmacology · 2025Review
- Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer.Tuberculosis and respiratory diseases · 2024Article
- Circulating tumor cells: from new biological insights to clinical practice.Signal transduction and targeted therapy · 2024Review
- MiRNAs and Microbiota in Non-Small Cell Lung Cancer (NSCLC): Implications in Pathogenesis and Potential Role in Predicting Response to ICI Treatment.International journal of molecular sciences · 2024Review
- Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors.BMC immunology · 2024Article
- Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.Frontiers in immunology · 2024Article
- Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer.Cancer science · 2023Article
- The Long Run towards Personalized Therapy in Non-Small-Cell Lung Cancer: Current State and Future Directions.International journal of molecular sciences · 2023Article
- Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients.Molecular oncology · 2023Article
- Experimental study on the suppressive effect of B3GNT3 on the apoptosis of lung adenocarcinoma cells and its application in early screening for lung adenocarcinoma.Journal of thoracic disease · 2023Article
- Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.Cell death & disease · 2023Review
- Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2023Review
- Landscape of tumor and immune system cells-derived exosomes in lung cancer: mediators of antitumor immunity regulation.Frontiers in immunology · 2023Review
- Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.Seminars in immunopathology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death (PD)-1 protein and its ligand, PD-L1, and cytotoxic T-lymphocyte-associated antigen (CTLA)-4, have revolutionized the management of patients with advanced non-small cell lung cancer (NSCLC). Unfortunately, only a small portion of NSCLC patients respond to these agents. Furthermore, although immunotherapy is usually well tolerated, some patients experience severe immune-related adverse events (irAEs). Liquid biopsy is a non-invasive diagnostic procedure involving the isolation of circulating biomarkers, such as circulating tumor cells (CTC), cell-free DNA (cfDNA), and microRNAs (miRNAs). Thanks to recent advances in technologies, such as next-generation sequencing (NGS) and digital polymerase chain reaction (dPCR), liquid biopsy has become a useful tool to provide baseline information on the tumor, and to monitor response to treatments. This review highlights the potential role of liquid biomarkers in the selection of NSCLC patients who could respond to immunotherapy, and in the identification of patients who are most likely to experience irAEs, in order to guide improvements in care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.